Physician profile
Uzma Ali
NPI 1235337254
$2,028.68
in general payments reported to CMS, 2019-2025
27 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $211 · 2021: $278 · 2022: $112 · 2023: $783 · 2024: $305 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.07 | 2021-2025 | Ubrelvy, Qulipta |
| Neurocrine Biosciences, INC. | $168.53 | 2022-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $164.76 | 2020-2023 | Austedo Xr, Ajovy |
| Edwards Lifesciences Corporation | $163.57 | 2023 | Hemosphere |
| Alexion Pharmaceuticals, INC. | $138.70 | 2024 | Ultomiris |
| Lundbeck LLC | $134.67 | 2021-2024 | Rexulti, Vyepti |
| Novartis Pharmaceuticals Corporation | $132.39 | 2019-2023 | |
| Genentech USA, INC. | $129.96 | 2023 | Ocrevus |
| Upsher-Smith Laboratories LLC | $111.77 | 2020-2022 | |
| Lilly USA, LLC | $96.56 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $86.10 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $53.65 | 2021 | |
| Amneal Pharmaceuticals LLC | $52.21 | 2023 | Rytary |
| Livanova USA, INC. | $50.49 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $37.39 | 2024 | Infinity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $37.12 | 2020 | |
| Medtronic USA, INC. | $36.11 | 2019 | |
| Acorda Therapeutics, INC | $33.45 | 2019-2020 | |
| Pfizer INC. | $32.12 | 2023-2024 | |
| Eisai INC. | $29.11 | 2025 | |
| Argenx US, INC. | $27.34 | 2022-2023 | Vyvgart Hytrulo |
| Genzyme Corporation | $20.02 | 2020 | |
| Boston Scientific Corporation | $19.08 | 2020 | |
| Amgen INC. | $15.99 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.36 | 2019 | |
| Grifols USA, LLC | $15.28 | 2019 | |
| Emd Serono, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.